NHSGGC Paediatrics for Health Professionals
Search RHCG Website
Select your language
Scroll back to top of page

Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (NICE TA878)

exp date isn't null, but text field is

Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19

Abstract

Published 28 March 2023.

Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.

The government, the NHS or the UK Health Security Agency may choose to use these treatments in a different way from that recommended in this guidance in exceptional circumstances such as:

  • the widespread incidence of variants of COVID-19 to which the general population has no natural or vaccine immunity
  • local or national high rates of hospitalisation with COVID-19.